Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9350999rdf:typepubmed:Citationlld:pubmed
pubmed-article:9350999lifeskim:mentionsumls-concept:C0035143lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C0021755lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C0085862lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1299583lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1704259lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1705987lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1314939lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1608386lld:lifeskim
pubmed-article:9350999lifeskim:mentionsumls-concept:C1549571lld:lifeskim
pubmed-article:9350999pubmed:issue2lld:pubmed
pubmed-article:9350999pubmed:dateCreated1997-11-28lld:pubmed
pubmed-article:9350999pubmed:abstractTextApolipoproteins A-II and C-III, which participate in the control of cholesterolemia and triglyceridemia, are negative acute phase proteins. Treatment of HepG2 cells with TNFalpha showed that apoA-II and apoC-III mRNA levels were decreased. Using transient transfection, we found that apoC-III gene expression is controlled at the transcriptional level. By competition and supershift experiments, we demonstrate that TNFalpha-induced complexes were related to C/EBPdelta/NF-IL6beta and p50 and that overexpression of C/EBPdelta was able to reproduce the inhibitory effect of TNFalpha on the apoC-III promoter. RT-PCR failed to detect the IL-1 transcript in TNFalpha-treated HepG2 cells, suggesting that activation of C/EBPdelta by TNFalpha is not related to the IL-1-signalling pathway.lld:pubmed
pubmed-article:9350999pubmed:languageenglld:pubmed
pubmed-article:9350999pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:citationSubsetIMlld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9350999pubmed:statusMEDLINElld:pubmed
pubmed-article:9350999pubmed:monthSeplld:pubmed
pubmed-article:9350999pubmed:issn0014-5793lld:pubmed
pubmed-article:9350999pubmed:authorpubmed-author:ParantMMlld:pubmed
pubmed-article:9350999pubmed:authorpubmed-author:ChambazJJlld:pubmed
pubmed-article:9350999pubmed:authorpubmed-author:LacorteJ MJMlld:pubmed
pubmed-article:9350999pubmed:authorpubmed-author:BeigneuxAAlld:pubmed
pubmed-article:9350999pubmed:issnTypePrintlld:pubmed
pubmed-article:9350999pubmed:day29lld:pubmed
pubmed-article:9350999pubmed:volume415lld:pubmed
pubmed-article:9350999pubmed:ownerNLMlld:pubmed
pubmed-article:9350999pubmed:authorsCompleteYlld:pubmed
pubmed-article:9350999pubmed:pagination217-20lld:pubmed
pubmed-article:9350999pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:meshHeadingpubmed-meshheading:9350999-...lld:pubmed
pubmed-article:9350999pubmed:year1997lld:pubmed
pubmed-article:9350999pubmed:articleTitleRepression of apoC-III gene expression by TNFalpha involves C/EBPdelta/NF-IL6beta via an IL-1 independent pathway.lld:pubmed
pubmed-article:9350999pubmed:affiliationCJF INSERM 9508 and URA-CNRS 1283, Paris, France.lld:pubmed
pubmed-article:9350999pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9350999lld:pubmed